PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 10, 20260 citationsOpen Access

Rare Inflammatory Myofibroblastic Tumor of the Urinary Bladder: A Case Report and Review of the Literature

View Full Paper
ŽVŽilvinas VenclovasATAgnė TalačkaitėGDGabija Dadurkaite

Key Points

  • To describe a rare inflammatory myofibroblastic tumor in the urinary bladder and its management.
  • Performed a literature review on inflammatory myofibroblastic tumors of the urinary bladder.
  • Documented a case of a 32-year-old female with bladder symptoms.
  • Conducted imaging and histopathological examinations after a misdiagnosis.
  • Executed transurethral resection to remove the tumor.
  • Documented a large bladder mass following persistent symptoms and misdiagnosis.
  • Confirmed diagnosis of an inflammatory myofibroblastic tumor through histopathological analysis.
  • Follow-up at 30 months showed no recurrence after treatment.

Abstract

Background: An inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal tumor, sometimes with urinary bladder involvement (though this is extremely uncommon). Due to its rarity, the exact etiology and optimal treatment strategy remain unclear. Methods: A review of the existing literature on IMT of the urinary bladder was performed. Results: We report a case of a 32-year-old female presenting with frequent urination, hematuria with clots, and lower abdominal pain for one month. Initially misdiagnosed as acute cystitis, the symptoms persisted despite antibiotic therapy. Laboratory findings revealed severe anemia, and imaging studies identified a large bladder mass. Transurethral resection of the bladder tumor (TURB) was performed, and a 96 g mass was removed. Histopathological examination confirmed IMT of the urinary bladder (IMTUB) with positive immunohistochemical staining for ALK, vimentin, and actin. Follow-up at 30 months showed no recurrence, with annual cystoscopy and CT scans confirming remission. Conclusions: IMTUB should be considered in young patients presenting with hematuria and lower urinary tract symptoms. Early diagnosis through cystoscopy, imaging, and histopathological confirmation is essential for appropriate management. TURB remains the gold standard for treatment, with ALK inhibitors providing additional therapeutic options in select cases. Long-term follow-up is necessary due to the unknown malignant potential of IMTUB.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Venclovas et al. (2026) studied this question.

synapsesocial.com/papers/69af95ee70916d39fea4e152https://doi.org/10.3390/jcm15052047
Ask AI
Helpful
Bookmark
Share
View Full Paper